BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Kisunla (Donanemab) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Kisunla (Donanemab)\, from ClinicalTrials
 .gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05026866-664@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Kisunla (Donanemab): Phase 3 readout est. (NCT05026866)
DESCRIPTION:Kisunla (Donanemab)\, phase 3\, Alzheimer's Disease.\nStudy: A 
 Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's D
 isease (TRAILBLAZER-ALZ 3)\nEstimated primary completion: November 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/donanemab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT05026866
URL:https://assetmemo.bio/drug/donanemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05508789-664@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Kisunla (Donanemab): Phase 3 readout est. (NCT05508789)
DESCRIPTION:Kisunla (Donanemab)\, phase 3\, Alzheimer's Disease.\nStudy: A 
 Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzh
 eimer's Disease (TRAILBLAZER-ALZ 5)\nEstimated primary completion: May 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/donanemab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05508789
URL:https://assetmemo.bio/drug/donanemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07589595-664@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Kisunla (Donanemab): Phase 2 readout est. (NCT07589595)
DESCRIPTION:Kisunla (Donanemab)\, phase 2.\nStudy: A Study of Donanemab (LY
 3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)\
 nEstimated primary completion: August 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/donanemab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07589595
URL:https://assetmemo.bio/drug/donanemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06911944-664@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Kisunla (Donanemab): Phase 4 readout est. (NCT06911944)
DESCRIPTION:Kisunla (Donanemab)\, phase 4\, Alzheimer's Disease.\nStudy: Am
 yloid Lowering for Alzheimer's in Down's With Donanemab Investigation\nEst
 imated primary completion: 31 December 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/donanemab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06911944
URL:https://assetmemo.bio/drug/donanemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07602582-664@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Kisunla (Donanemab): Phase 3 readout est. (NCT07602582)
DESCRIPTION:Kisunla (Donanemab)\, phase 3\, Alzheimer's Disease.\nStudy: A 
 Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (T
 RAILBLAZER-ALZ 3-EXT).\nEstimated primary completion: September 2029. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/donanemab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07602582
URL:https://assetmemo.bio/drug/donanemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07571161-664@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Kisunla (Donanemab): Phase 3 readout est. (NCT07571161)
DESCRIPTION:Kisunla (Donanemab)\, phase 3\, Alzheimer's Disease.\nStudy: Do
 nanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpai
 red (Preclinical) Alzheimer's Disease\nEstimated primary completion: April
  2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/donanemab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07571161
URL:https://assetmemo.bio/drug/donanemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06996730-664@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Kisunla (Donanemab): Phase 2/3 readout est. (NCT06996730)
DESCRIPTION:Kisunla (Donanemab)\, phase 2/3\, Alzheimer's Disease.\nStudy: 
 A Study of Donanemab\, RG6289\, or the Combination of Donanemab and RG6289
  in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Auto
 somal-Dominant Alzheimer's Disease\nEstimated primary completion: 1 June 2
 030. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/donanemab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06996730
URL:https://assetmemo.bio/drug/donanemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07838155-664@assetmemo.bio
DTSTAMP:20261121T004031Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Kisunla (Donanemab): Phase 4 readout est. (NCT07838155)
DESCRIPTION:Kisunla (Donanemab)\, phase 4\, Alzheimer's Disease.\nStudy: A 
 Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzh
 eimer's Disease\nEstimated primary completion: September 2030. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/donanemab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07838155
URL:https://assetmemo.bio/drug/donanemab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
